---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-043741"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2026-02-10T23:59:59+00:00"
generated_at: "2026-05-16T03:38:10.922960+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Galecto CEO departs; authorized shares increased to 500M; outstanding shares jump to 43.6M after preferred conversion

## Summary
- CEO Hans T. Schambye departs effective Feb 10, 2026; COO Sherwin Sattarzadeh appointed interim principal executive officer.
- Shareholders approve increase in authorized common shares from 300M to 500M, plus Cayman Islands redomestication.
- Automatic conversion of Series C Preferred yields ~42M new shares; total outstanding rises from ~1.6M to ~43.6M.
- Shareholders also approve 2026 Equity Incentive Plan and Employee Stock Purchase Plan.
- Separation agreement for Schambye includes lump-sum base salary continuation, pro-rated bonus, and full equity acceleration.

## SEC filing metadata
- accession: 0001193125-26-043741
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2026-02-10T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 5.02, 5.03, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000119312526043741/0001193125-26-043741-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000119312526043741/glto-20260206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-043741
- JSON: https://secwatch.observer/filing/0001193125-26-043741.json
- Plain text: https://secwatch.observer/filing/0001193125-26-043741.txt

## Source-grounded claims
- claim_id: 01263a68d9f80e06af4a3a569e5749a2ea5d2b0d
  claim: Damora Therapeutics, Inc.: Certificate of Amendment to increase authorized shares of common stock from 300,000,000 to 500,000,000, effective upon filing on February 9, 2026 (effective 2026-02-09).
  evidence_excerpt: On February 9, 2026, in connection with the approval by stockholders of the Company at a special meeting of stockholders (the “Special Meeting”) as described in Item 5.07 below, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock, par value $0.00001 per share (“Common Stock”), from 300,000,000 to 500,000,000, which became effective upon filing.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800315/000119312526043741/0001193125-26-043741-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.